• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Prostin E2 – Sterile Solution
    / Pfizer

    Active Ingredient
    Dinoprostone 10 mg/ml

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    0.5 ml

    partial basket chart 35607 16674

    Related information


    See prescribing information for full details.


    As a therapeutic abortifacient during the first or second trimester of pregnancy. For evacuation of the uterus in cases of missed abortion. Can be used as an alternative measure to complete therapeutic termination of pregnancy when intra-amniotic saline injections have failed. Clinical experience to date indicates that administration by the extra-amniotic route is more effective and better tolerated than by the I.V. route.


    History of hypersensitivity to prostaglandins. The extra-amniotic route of administration should not be employed in the presence of cervicitis or vaginal infections. Patients already receiving I.V. oxytocic drugs.

    Special Precautions

    If abortion does not occur, or is suspected to be incomplete as a result of prostaglandin therapy, the appropriate treatment for complete evacuation of the pregnant uterus should be instituted in all instances. The product should only be used where 24 hours medicdbal cover is provided. Patients with: glaucoma or raised intraocular pressure; asthma or history thereof; epilepsy or a history thereof; active cardiac, pulmonary, renal or hepatic disease; hypertension; compromised (scarred) uteri. Patients with known pelvic infections should receive adequate treatment prior to attempting to induce termination of pregnancy.

    Side Effects

    Effects have generally been dose dependent, transient, and reversible on discontinuation of therapy. Nausea and/or vomiting and diarrhea. Flushing, shivering, headache, and dizziness. Rare events that should be noted: Hypersensitivity, uterine rupture and cardiac arrest. Pulmonary/amniotic fluid embolism; uterine hypercontractility or hypertonus; systemic (maternal) hypertension; bronchospasm/asthma; rapid cervical dilation; fever; back ache; rash. A temporary pyrexia and elevated WBC are not unusual, but both have reverted after termination of therapy.

    Drug interactions

    Oxytocin or other oxytocics.

    PFIZER Manufacturing Belgium NV, Belgium